Title |
The protective effects of plasma gelsolin on stroke outcome in rats
|
---|---|
Published in |
Experimental & Translational Stroke Medicine, November 2011
|
DOI | 10.1186/2040-7378-3-13 |
Pubmed ID | |
Authors |
Huong T Le, Aaron C Hirko, Jeffrey S Thinschmidt, Maria Grant, Zhimin Li, Joanna Peris, Michael A King, Jeffrey A Hughes, Sihong Song |
Abstract |
To date, recombinant tissue plasminogen activator (rtPA) is the only approved drug for ischemic stroke. It is intravenously administered functioning as a thrombolytic agent and is used to obtain reperfusion of the affected area of the brain. Excitotoxicity, inflammation and apoptosis are all involved in delayed neuronal death following stroke and offer multiple opportunities to intervene with neuroprotective agents. Gelsolin (GSN) is an actin- and calcium-binding protein mediating the disassembly of actin filaments and activity of calcium channels. It also functions as a regulator of apoptosis and inflammatory responses. This study tests the hypothesis that increasing the concentration of the form of GSN known as plasma GSN (pGSN) near an infarct will provide neuroprotection following ischemic stroke. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 24 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 4 | 17% |
Researcher | 4 | 17% |
Student > Doctoral Student | 2 | 8% |
Professor | 2 | 8% |
Student > Master | 2 | 8% |
Other | 4 | 17% |
Unknown | 6 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 29% |
Agricultural and Biological Sciences | 4 | 17% |
Biochemistry, Genetics and Molecular Biology | 1 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Psychology | 1 | 4% |
Other | 3 | 13% |
Unknown | 7 | 29% |